Skip to content

To keep going please Log in.

or

By submitting my information, I agree to the Privacy Policy and Terms of Service.

To keep going please Log in.

or

By submitting my information, I agree to the Privacy Policy and Terms of Service.

To keep going please Log in.

or

By submitting my information, I agree to the Privacy Policy and Terms of Service.

To keep going please Log in.

or

By submitting my information, I agree to the Privacy Policy and Terms of Service.

ARMP Armata Pharmaceuticals, Inc. Common Stock
$10.96 0.00% 0.00
Notify me if price changes either direction
Interactive Brokers Logotype

Buy ARMP stocks now with Interactive Brokers – the most advanced investment platform

Contents
  • Performance
  • Key stats
  • Financials
  • US politician trades
Loading

Key Stats

Market cap. 399.0M
Enterprise value 575.6M
Trailing PE -21.076923150283
Forward PE -7.2678337
PEG Ratio -0.053585397839702
Enterprise to EBITDA -18.069
Enterprise to revenue 113.897
Price to book MRQ -4.1536603442056
Price to sales TTM 82.19647

Financials

Fiscal Year Ends 2024-12-31
Most Recent Quarter (MRQ) 2025-09-30
Revenue (TTM) 5.1M
EBITDA -31857000
Diluted EPS TTM -1.66
Total Cash (MRQ) 14.8M
Current ratio (MRQ) 0.121
Operating Cash Flow (TTM) -27016000

ARMP trades by the US politicians

Percentage
0% 0 sells
100% 0 buys
Amount
$0 0 sells
$0 0 buys
In the last 0 months

Recent ARMP News

Home

IMPORTANT NOTICE

Finbold is a news and information website. This Site may contain sponsored content, advertisements, and third-party materials, for which Finbold expressly disclaims any liability.

RISK WARNING: Cryptocurrencies are high-risk investments and you should not expect to be protected if something goes wrong. Don’t invest unless you’re prepared to lose all the money you invest. (Click here to learn more about cryptocurrency risks.)

By accessing this Site, you acknowledge that you understand these risks and that Finbold bears no responsibility for any losses, damages, or consequences resulting from your use of the Site or reliance on its content. Click here to learn more.